Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7855707 | 0.87 | CYP1A1 (0.52) | CYP1A1MAOBCYP1B1RAB9A | |
| SCHEMBL7202454 | 0.87 | MAPT (0.46) | SRD5A2RAB9A | |
| SCHEMBL7204230 | 0.84 | APP (0.47) | CES2CES1PTPN1GRM5FFAR1 | |
| SCHEMBL7199088 | 0.83 | KCNA5 (0.42) | TLR7RAB9A | |
| SCHEMBL7200606 | 0.83 | APP (0.49) | CES2GRM5FFAR1RAB9A | |
| SCHEMBL7843701 | 0.83 | RAB9A (0.43) | CYP1A1MAOBCYP1B1FFAR1RAB9A | |
| SCHEMBL7202747 | 0.82 | HSP90AA1 (0.49) | CES1GRM5FFAR1RAB9A | |
| SCHEMBL7203523 | 0.81 | RAB9A (0.49) | CES2CES1GSK3BFFAR1RAB9A | |
| SCHEMBL7201310 | 0.81 | VCP (0.57) | CES2CES1GRM5FFAR1RAB9A | |
| SCHEMBL7204585 | 0.81 | APP (0.51) | CES2CES1GSK3BGRM5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605730-B2 | 3-(2-Thienyl)-5-phenyl-1H-pyrazole compounds of given formula | NIHON BAYER AGROCHEM K.K. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20030028034-A1 | Nematicidal pyrazoles | WADA KATSUAKI (JP) | 2003-02-06 | — | — | US | disclosed |
| US-6310049-B1 | 3-(2-THIENYL),5-(SUBSTITUTED PHENYL)-1H-PYRAZOLES AND 3-(SUBSTITUTED PHENYL),5-(2-THIENYL)-1H-PYRAZOLES OF GIVEN FORMULA; ANTHELMINTICS | NIHON BAYER AGROCHEM K.K. (JP) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028034-A1 | Nematicidal pyrazoles | CBR3, CBR1, CCR4 | CES2 133/4885CES1 134/4885PTPN1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.